Orphazyme A/S :Has Decided To Adjust Its Outlook For 2022.Change Is Driven By Separation Of Activities Into Continuing And Discontinued Operations.Expect To End 2022 With More Than Dkk 30 Million In Cash And Equivalents.For Full-Year 2022, We Anticipate A Loss From Continuing Operations In Range Dkk 40 Million - 45 Million.For Full-Year 2022, We Anticipate A Positive Result From Discont Operations Relating To The Sale Of Assets To Kempharm Of Dkk 87.4 Million.